Reported Saturday, Cogent Biosciences Highlights SUMMIT Data At AAAAI 2026, Bezuclastinib Delivers –32.0 Point Mean TSS Reduction At 48 Weeks With 99% Achieving ≥50% Serum Tryptase Reduction
Cogent Biosciences, Inc. -0.09%
Cogent Biosciences, Inc. COGT | 35.21 | -0.09% |
- Bezuclastinib mean TSS reduction deepens to –32.0 points at 48 weeks of treatment with further improvement shown across all measured symptoms
- 99% of patients achieve >50% reduction in serum tryptase at 48 weeks, with 83% rate of normalization
- Strong evidence of bezuclastinib's potential as first disease modifying agent for NonAdvSM patient population given clear correlation between objective measures of disease burden and symptomatic improvement